Review and Hypothesis: Vulnerable plaque formation from obstruction of vasa vasorum by homocysteinylated and oxidized lipoprotein aggregates complexed with microbial remnants and LDL autoantibodies

Annals of Clinical and Laboratory Science

Volumn 39, Issue 1, 2009, Pages 3-16

  Ravnskov, Uffe ^a   McCully, Kilmer S ^b,c  

^a Boston Veterans Affairs Healthcare System ^*  (Sweden)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autoimmunity; Hyperhomocysteinemia; Lipoprotein aggregates; Microbial remnants; Oxidized LDL; Vasa vasorum; Vulnerable plaque

Indexed keywords

APOLIPOPROTEIN B; AUTOANTIBODY; CHOLESTEROL; HOMOCYSTEINE THIOLACTONE; LOW DENSITY LIPOPROTEIN;

ABSCESS; ANTIBODY PRODUCTION; ARTERY WALL; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; BACTEREMIA; BLOOD VESSEL OCCLUSION; BLOOD VESSEL RUPTURE; CAPILLARY; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CELL DEATH; COMPLEX FORMATION; HEART INFARCTION; HIGH TEMPERATURE; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOSTIMULATION; INFECTION; INFLAMMATION; INTIMA; ISCHEMIA; LEUKOCYTE; MICROBIAL GROWTH; NECROSIS; PRECIPITATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SEPSIS; THROMBOSIS; TISSUE PRESSURE; VASA VASORUM;

EID: 60249084384     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Hansson GK, Nilsson J. Introduction: atherosclerosis as inflammation: a controversial concept becomes accepted. J Int Med 2008;263:462-463.
2. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241.
3. Hansson GK, Heistad DD. Two views on plaque rupture. Arterioscler Thromb Vasc Biol 2007;27:697.
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. NEJM 2005;352:1685-1695.
5. Reis SE, Holubkov R, Conrad-Smith AJ, Kelsey SF, Sharaf BL, Reichek N, Rogers WJ, Merz CN, Sopko G, Pepine CJ. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001;141:735-741.
6. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
7. McCully KS. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med 2005;43:980-986.
8. Ravnskov U. Is atherosclerosis caused by high cholesterol? Q J Med 2002;95:397-403.
9. Ravnskov U. High cholesterol may protect against infections and atherosclerosis. Q J Med 2003;96:927-934.
10. Miettinen TA, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Long-term follow-up of 96 patients. Arteriosclerosis 1988;8:163-167.
11. Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SE. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2001;87:547-453.
12. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991;11:290-297.
13. Ferrières J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995;92:290-295.
14. Neil HAW, Seagroatt V, Betteridge DJ, Cooper MP, Durrington PN, Miller JP, Seed M, Naoumova RP, Thompson GR, Huxley R, Humphries SE. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterol-aemia. Heart 2004; 90:1431-1437.
15. Jansen AC, van Aalst-Cohen ES, Tanck MW, Cheng S, Fontecha MR, Li J, Defesche JC, Kastelein JJ. Genetic determinants of cardiovascular disease risk in familial hyper-cholesterolemia. Arterioscler Thromb Vasc Biol 2005;25:1475-1481.
16. Sugrue DD, Trayner I, Thompson GR, Vere TV, Dimeson J, Stirling Y, Meade TW. Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia. Br Heart J 1985;53:265-268.
17. Calara F, Silvestre M, Casanada F, Yean N, Napoli C, Palinski W. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol 2001;195:257-263.
18. Naruszewicz M, Mirkiewicz E, Olszewski AJ, McCully KS. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovas Dis 1994;4:70-77.
19. Thayer WS. On the cardiac and vascular complications and sequels of typhoid fever. Bull Johns Hopkins Hosp 1904;Oct:323-340.
20. Wiesel J. Die Erkrankungen arterieller Gefässe im Verlaufe akuter Infektionen. II Teil. Z Heilkunde 1906;27:262-294.
21. Osler W. Diseases of the arteries. In: Modern Medicine: its Practice and Theory (Osler W, Ed), Lea & Fibiger, Philadelphia, 1908; pp 426-447.
22. Klotz O, Manning MF. Fatty streaks in the intima of arteries. J Pathol Bacteriol 1911;16:211-220.
23. Grayston JT, Kuo CC, Campbell LA, Benditt EP. Chlamydia pneumoniae strain TWAR and atherosclerosis. Eur Heart J 1993;Suppl K:66-71.
24. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J 1993;Suppl K:30-38.
25. Nicholson AC, Hajjar DP. Herpesvirus in atherosclerosis and thrombosis. Etiologic agents or ubiquitous bystanders? Arterioscler Thromb Vasc Biol 1998;18:339-348.
26. Ismail A, Khosravi H, Olson H. The role of infection in atherosclerosis and coronary artery disease. A new therapeutic target. Heart Dis 1999;1:233-240.
27. Kuvin JT, Kimmelstiel MD. Infectious causes of atherosclerosis. Am Heart J 1999;137:216-226.
28. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells SW. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007;28:1205-1210.
29. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. NEJM 2004;351:2611-2618.
30. Valtonen V, Kuikka A, Syrjanen J. Thrombo-embolic complications in bacteremic infections. Eur Heart J 1993;14Suppl K:20-23.
31. Spahr A, Klein E, Khuseyinova N, Boeckh C, Muche R, Kunze M, Rothenbacher D, Pezeshki G, Hoffmeister A, Koenig W. Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the Coronary Event and Periodontal Disease (CORODONT) study. Arch Intern Med 2006;166:554-549.
32. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, Hafner G, Prellwitz W, Schlumberger W, Meyer J. Impact of infectious burden on progression of carotid atherosclerosis. Stroke 2002;33:2581-2586.
33. Pesonen E. Infection and intimal thickening: evidence from coronary arteries in children. Eur Heart J 1994;15Suppl C:57-61.
34. Liuba P, Persson J, Luoma J, Yla-Herttuala S, Pesonen E. Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima-media. Eur Heart J 2003;24:515-521.
35. Todd EW, Coburn AF, Hill AB. Antistreptolysin S titres in rheumatic fever. Lancet 1939;2:1213-1217.
36. Stollerman GH, Bernheimer AW. Inhibition of streptolysin S by the serum of patients with rheumatic fever and acute streptococcal pharyngitis. J Clin Invest 1950;29:1147-1155.
37. Humphrey JH. The nature of antistreptolysin S in the sera of man and of other species; the lipoprotein properties of antistreptolysin S. Br J Exp Pathol 1949;30:365-375.
38. Stollerman GH, Bernheimner AW, MacLeod CM. The association of lipoproteins with the inhibition of streptolysin S by serum. J Clin Invest 1950;29:1636-1645.
39. Skarnes RC. In vivo interaction of endotoxin with a plasma lipoprotein having esterase activity. J Bacteriol 1968;95:2031-2034.
40. Shortridge KF, Ho WK, Oya A, Kobayashi M. Studies on the inhibitory activities of human serum lipoproteins for Japanese encephalitis virus. Southeast Asian J Trop Med Public Health 1975;6:461-466.
41. Whitelaw DD, Birkbeck TH. Inhibition of staphylococcal delta-hemolysin by human serum lipoproteins. FEMS Microbiology Letters 1978;3:335-339.
42. Freudenberg MA, Galanos C. Interaction of lipopolysaccharides and lipid A with complement in rats and its relation to endo-toxicity. Infect Immun 1978;19:875-882.
43. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide- high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981;67:827-837.
44. Bhakdi S, Tranum-Jensen J, Utermann G, Fussle R. Binding and partial inactivation of Staphylococcus aureus alpha-toxin by human plasma low density lipoprotein. J Biol Chem 1983;258:5899-5904.
45. Seganti L, Grassi M, Mastromarino P, Pana A, Superti F, Orsi N. Activity of human serum lipoproteins on the infectivity of rhabdoviruses. Microbiologica 1983;6:91-99.
46. Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. PNAS USA 1986;83:2704-2708.
47. Huemer HP, Menzel HJ, Potratz D, Brake B, Falke D, Utermann G, Dierich MP. Herpes simplex virus binds to human serum lipoprotein. Intervirology 1988;29:68-76.
48. Flegel WA, Wölpl A, Männel DN, Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989;57:2237-2245.
49. Cavaillon JM, Fitting C, Haeffner-Cavaillon N, Kirsch SJ, Warren HS. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun 1990;58:2375-2382.
50. Northoff H, Flegel WA, Yurttas R, Weinstock C. The role of lipoproteins in inactivation of endotoxin by serum. Beitr Infusionsther 1992;30:195-197.
51. Superti F, Seganti L, Marchetti M, Marziano ML, Orsi N. SA-11 rotavirus binding to human serum lipoproteins. Med Microbiol Immunol 1992;181:77-86.
52. Weinstock C, Ullrich H, Hohe R, Berg A, Baumstark MW, Frey I, Northoff H, Flegel WA. Low density lipoproteins inhibit endotoxin activation of monocytes. Arterioscler Thromb 1992;12:341-347.
53. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low-and high-density lipoproteins and by apolipoprotein A-1. Infect Immun 1993;61:5140-5146.
54. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995;63:2041-2046.
55. Netea MG, Demacker PNM, Kullberg BJ, Boerman OC, Verschueren I, Stalenhoef AF, van der Meer JW. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe Gram-negative infections. J Clin Invest 1996;97:1366-1372.
56. Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC, Seidman CE, Tremaroli JD, Lai J, Rubin AL. A single intravenous dose of endotoxin rapidly alters serum lipo-proteins and lipid transfer proteins in normal volunteers. J Lipid Res 2003;44:1489-1498.
57. Guyton JR, Klemp KF. Transitional features in human atherosclerosis. Intimal thickening, cholesterol clefts, and cell loss in human aortic fatty streaks. Am J Pathol 1993;143:1444-1457.
58. Van Amersfoort ES, Van Berkel TJC, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003;16:379-414.
59. Khovidhunkit W, Kim M-S, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169-1196.
60. Heinecke JW, Suits AG, Aviram M, Chait A. Phagocytosis of lipase-aggregated low density lipoprotein promotes macrophage foam cell formation. Sequential morphological and biochemical events. Arterioscler Thromb 1991;11:1643-1651.
61. Kalayoglu MV, Indrawati, Morrison RP, Morrison SG, Yuan Y, Byrne GI. Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis 2000;181Suppl 3:S483-489.
62. Qi M, Miyakawa H, Kuramitsu HK. Porphyromonas gingivalis induces murine macrophage foam cell formation. Microb Pathog 2003;35:259-267.
63. Madjid M, Vela D, Khalili-Tabrizi H, Casscells SW, Litovsky S. Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes. Tex Heart Inst J 2007;34:11-18.
64. Welch CL, Sun Y, Arey BJ, Lemaitre V, Sharma N, Ishibashi M, Sayers S, Li R, Gorelik A, Pleskac N, Collins-Fletcher K, Yasuda Y, Bromme D, D'Armiento JM, Ogltree ML, Tall AR. Spontaneous thrombosis and medial degeneration in Apo3-/-, Npc1-/-mice. Circulation 2007;116:2444-2452.
65. Noble NL, Boucek RJ, Kao KY. Biochemical observations of human atheromatosis: analysis of aortic intima. Circulation 1957;15:366-372.
66. Bonnefont-Rousselot D, Therond P, Beaudeux JL, Peynet J, Legrand A, Delattre J. High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis. Clin Chem Lab Med 1999;37:939-948.
67. Fabricant CG, Krook L, Gillespie JH. Virus-induced cholesterol crystals. Science 1973;181:566-567.
68. Benesch R, Benesch RE. Thiolation of proteins. PNAS USA 1958;44:848-853.
69. Vidal M, Sainte-Marie J, Philippot J, Bienvenue A. Thiolation of low-density lipoproteins and their interactions with L2C leukemic lymphocytes. Biochimie 1986;68:723-730.
70. Ferguson E, Parthasarathy S, Joseph J, Kalyanaraman B. Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low density lipoprotein. J Lipid Res 1998;39:925-933.
71. Undas A, Jankowski M, Twardowska M, Padjas A, Jakubowski H, Szczeklik A. Antibodies to N-homocysteinylated albumin as a marker for early-onset coronary artery disease in men. Thromb Haemost 2005;93:346-350.
72. Yang X, Gao Y, Zhou J, Yang Y, Wang J, Song L, Liu Y, Xu H, Chen Z, Hui R. Plasma homocysteine thiolactone adducts associated with risk of coronary heart disease. Clin Chim Acta 2006;364:230-234.
73. Perla-Kajan J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 2007;32:561-572.
74. Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galezzi M, Pasini FL. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007;6:503-509.
75. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphoryl choline of oxidized phospholipids. PNAS USA 2002;99:13043-13048.
76. Uusitupa MI, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R, Ylä-Herttuala S. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:1236-1242.
77. Leinonen JS, Rantalaiho V, Laippala P, Wirta O, Pasternack A, Alho H, Jaakkola O, Ylä-Herttuala S, Koivula T, Lehtimäki T. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus. Free Radic Res 1998;29:137-141.
78. Wilson PW, Ben-Yehuda O, McNamara J, Massaro J, Witztum J, Reaven PD. Autoantibodies to oxidized LDL and cardiovascular risk: the Framingham Offspring Study. Atherosclerosis 2006;189:364-368.
79. Mayr M, Kiechl S, Tsimikas S, Miller E, Sheldon J, Willeit J, Witztum JL, Xu Q. Oxidized low-density lipoprotein auto-antibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol 2006;47:2436-2443.
80. Tsimikas S, Aikawa M, Miller RJ Jr, Miller ER, Torzewski M, Lentz SR, Bergmark C, Heistad DD, Libby P, Witztum JL. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol 2007;27:175-181.
81. Schumacher M, Eber B, Tatzber F, Kaufmann P, Halwachs G, Fruhwald FM, Zweiker R, Esterbauer H, Klein W. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic Biol Med 1995;18:1087-1091.
82. Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegård J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006;188:160-166.
83. Sjoberg BG, Su J, Dahlbom I, Gronlund H, Wikstrom M, Hedblad B, Berglund G, de Faire U, J, Frostegård. Low levels of IgM antibodies against phosphorylcholine-a potential risk marker for ischemic stroke in men. Atherosclerosis 2007, doi:10.1016/j.atherosclerosis.2008.07.009.
84. Ramirez J. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with atherosclerosis. Ann Int Med 1996;125:979-982.
85. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997;176:292-295.
86. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998;31:827-837.
87. Kuo C-C, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Inf Dis 1993; 167:841-849.
88. Campbell LA, O'Brien ER, Capuccio AL, Kuo C-C, Wang S-P, Stewart D, Patton DL, Cummings PK, Grayston JT. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Inf Dis 1995;172:285-288.
89. Vink A, Pasterkamp G, Poppen M, Schonfeld AH, deKleijn DPV, Roholl PJM, Fontijn J, Plomp S, Borst C. The adventitia of atherosclerotic coronary arteries frequently contains Chlamydia pneumoniae. Atherosclerosis 2001;157:117-122.
90. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-3566.
91. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50:127-134.
92. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. NEJM 2002;347:5-12.
93. Madjid M, Naghavi M, Malik BA, Litovsky S, Willerson JT, Casscells SW. Thermal detection of vulnerable plaque. Am J Cardiol 2002;90:36L-39L.
94. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002;106:2894-2900.
95. Costantini M, Tritto C, Licci E, Sticchi G, Capone S, Montiaro A, Bruno A, Nuzzaci G, Picano E. Myocarditis with ST-elevation myocardial infarction presentation in young men. A case series of 11 patients. Int J Cardiol 2005;101:157-158.
96. Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, Hochman JS; SHOCK Investigators. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005;165:1643-1650.
97. Spagnoli LG, Pucci S, Bonanno E, Cassone A, Sesti F, Ciervo A, Mauriello A. Persistent Chlamydia pneumoniae infection of cardiomyocytes is correlated with fatal myocardial infarction. Am J Pathol 2007;170:33-42.
98. Stary HC. Macrophages, macrophage foam cells, and eccentric intimal thickening in the coronary arteries of young children. Atherosclerosis 1987;64:91-108.
99. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989;9(1 Suppl):I19-32.
100. Ritman EL, Lerman A. The dynamic vasa vasorum. Cardiovasc Res 2007;75:649-658.
101. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HR. Risk of myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165:978-984.
102. Ott SJ, El Mokhtari NE, Musfeldt M, Hellmig S, Freitag S, Rehman A, Kuhbacher T, Nikolaus S, Namsolleck P, Blaut M, Hampe J, Sahly H, Reinecke A, Haake N, Gunther R, Kruger D, Lins M, Herrmann G, Folsch UR, Simon R, Schreiber S. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006;113:929-937.
103. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983;2:644-647.
104. Pampou SY, Gnedoy SN, Bystrevskaya VB, Smirnov VN, Chazov EI, Melnick JL, DeBakey ME. Cytomegalovirus genome and the immediate-early antigen in cells of different layers of human aorta. Virchows Arch 2000;436:539-552.
105. Shi Y, Tokunaga O. Chlamydia pneumoniae and multiple infections in the aorta contribute to atherosclerosis. Pathol Int 2002;52:755-763.
106. Gieffers J, Füllgraf H, Jahn J, Klinger M, Dalhoff K, Katus H A, Solbach W, Maass M. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001;103:351-356.
107. Katz JT, Shannon RP. Bacteria and coronary atheroma: more fingerprints but no smoking gun. Circulation 2006;113:920-922.
108. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. Brit Med J 2001;322:1019-1023.
109. Elias ER, Irons MB, Hurley AD, Tint GS, Salen G. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet 1997;68:305-310.
110. Yuan C, Mitsumori LM, Beach KW, Maravilla KR. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology 2001;221:285-299.
111. Fleiner M, Kummer M, Mirlacher M, Sauter G, Cathomas G, Krapf R, Biedermann BC. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation 2004;110:2843-2850.
112. Curcio CA, Millican CL, Bailey T, Kruth HS. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci 2001;42:265-274.
113. Schonholzer KW, Waldron M, Magil AB. Intraglomerular foam cells and human focal glomerulosclerosis. Nephron 1992;62:130-136.
114. Lee HS, Kruth HS. Accumulation of cholesterol in the lesions of focal segmental glomerulosclerosis. Nephrology 2003;8:224-230.
115. Crouse JR, Grundy SM, Ahrens EH. Cholesterol distribution in the bulk tissues of man: variation with age. J Clin Invest 1972; 51:1292-1296.
116. McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 2007;86(Suppl):1563S-1568S.
117. Stoney CM. Plasma homocysteine levels increase in women during psychological stress. Life Sciences 1999;64:2359-2365.
118. Stoney CM, Engebretson TO. Plasma homocysteine concentrations are positively associated with hostility and anger. Life Sciences 2000;66:2267-2275.
119. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J 1989,117:1177-1188.
120. Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol 2006;55:251-258.
121. Ravnskov U. The fallacies of the lipid hypothesis. Scand Cardio-vasc J 2008;42:236-239.